University of Michigan | Strategic Alliance Partners

Roughly one-third of women with early-stage breast cancer develop intolerable adverse effects during aromatase inhibitor therapy.

Researchers are urging oncologists to improve the communication of complex medical information to their patients.

A class of drugs that has shown encouraging results in breast and ovarian cancers with BRCA gene mutations may also benefit patients who have colorectal cancers